Our study has shown that this detection of anti-tTG-IgA and anti-DGP-IgG has the best overall performance in the diagnosis of CD, and that anti-DGP-IgG has a comparable diagnostic value as anti-tTG-IgA. usage of PCPs led to the correct identification of all CD patients. In our study, PCPs showed 100% agreement with 3-Hydroxydecanoic acid the histopathological results. PCP IgA test showed a 98% concordance and correlated positively (R = 0.651, = 0.0014) with EliA Celikey test. The highest specificity and positive predictive value (both 100%) were observed for the detection of Polycheck anti-tTG-IgA antibodies. The highest sensitivity and negative predictive value (both 100%) were achieved by Polycheck anti-DGP-IgG antibody detection. The best performance (98% sensitivity and negative predictive value, 100% specificity and positive predictive value, diagnostic accuracy – AU ROC 99%) was observed for the strategy of using both PCP IgA and IgG and determining positive outcomes of the test with two or more coeliac-specific antibodies detected. The majority of coeliac patients had multiple antibodies. All four antibodies were detected in 7 (14%) cases, 19 children (38%) were positive for three antibodies and 23 (46%) were positive 3-Hydroxydecanoic acid for two antibodies. CONCLUSION: The present study showed that detection of coeliac-specific antibodies with multi-antibody PCPs is effective and efficacious in the diagnosis of CD. Keywords: Coeliac disease, Tissue transglutaminase, Deamidated gliadin peptides, Multi-antibody tests, Polycheck celiac panels Core tip: Detection 3-Hydroxydecanoic acid of coeliac-specific antibodies has become a useful tool in the diagnostics of coeliac disease. Different serology test combinations have been found to improve diagnosis in comparison to a single antibody test. Recently, multi-antibody strategy has been implemented in immunoassays. In this study we have found that multi-parametric quantitative Polycheck immunoassay is 3-Hydroxydecanoic acid reliable in reference to intestinal biopsy results and measurements of anti-tissue transglutaminase-IgA by a reference method. The best FRP overall clinical performance was obtained by a combination of both IgA and IgG panels, with two and more positively detected antibodies, to determine the outcome. INTRODUCTION Coeliac disease (CD) is a chronic immune-based systemic disorder caused by intolerance to dietary gluten in individuals with genetic predisposition. Gluten is a storage protein in wheat, barley, and rye, which triggers an inflammatory state in the small intestine, leading to the induction of the cytotoxic intra-epithelial 3-Hydroxydecanoic acid lymphocytes, reduction of villus height, hyperplastic cryptae and finally to complete villus atrophy. CD is characterised by the presence of specific antibodies, including specific ones against a disease inducing factor: Deamidated gliadin peptides (DGP), as well as autoantibodies against tissue transglutaminase 2 (tTG). Assessing the levels of serum antibodies that were applied in the diagnosis of CD for over 40 years, starting from the determination of anti-gliadin and anti-reticulin antibody levels[1]. The discovery that a major target of autoantibodies in CD is tTG, which is related to deamidation of gliadin peptides by this enzyme, allowed to better understand the pathogenic pathway of events leading to CD development[2,3]. In recent years, the usage of native gliadin as the target of serology diagnostics of CD was withdraw from the CD routine diagnosis due to inferior performance compared to a highly specific and sensitive anti-tTG tests[4]. Deamidation of gliadin peptides enhances their immunogenicity, which leads to a higher specificity and sensitivity of tests for anti-DGP-IgA and -IgG antibodies than native gliadin tests[4,5]. Studies on the performance of anti-DGP-IgG tests in the diagnosis of CD showed that it is comparable with anti-tTG-IgA tests[6,7]. In contrast to anti-tTG-IgA, anti-DGP-IgG tests are not affected by the presence of hemolysis in a tested serum sample[8] and are effective in the detection of CD in patients with selective IgA deficiency[4,9]. The European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) published, in 2012[10], clinical guidelines including algorithms of CD diagnosis with the crucial role of serology tests. According to ESPGHAN recommendations, the initial approach to patients with suspected CD includes serological screening for.